KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.73
-0.04 (-4.82%)
Open$0.75
Previous Close$0.76
Day High$0.78
Day Low$0.71
52W High$23.54
52W Low$13.49
Volume—
Avg Volume81.9K
Market Cap16.74M
P/E Ratio28.78
EPS$0.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,613.1% upside
Current
$0.73
$0.73
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.90M | 3.72M | 4.29M |
| Net Income | 467.4K | 601.6K | 528.1K |
| Profit Margin | 12.0% | 16.2% | 12.3% |
| EBITDA | 1.16M | 1.10M | 1.24M |
| Free Cash Flow | 801.3K | 617.9K | 781.1K |
| Rev Growth | +18.2% | +4.0% | +10.0% |
| Debt/Equity | 0.89 | 0.81 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |